Archives

Circadian Therapeutics to Attend JP Morgan Healthcare Conference

Circadian Therapeutics to Attend JP Morgan Healthcare Conference Circadian Therapeutics to attend JP Morgan Healthcare Conference in San Francisco Dr Mark Sampson, CEO will be attending the JP Morgan Healthcare Conference in person from 9th -12th January 2022....

CT1500 Phase 1 Study

CT1500 Phase 1 Study CT1500 Phase 1 Study Circadian Therapeutics announces the first subject recruited to Phase I study for CT-1500, marks move to a clinical stage company • First subject dosed for Phase I study• CT-1500 being developed to treat Non-24 Sleep-Wake...

Circadian Therapeutics and Arquimea Collaboration

Circadian Therapeutics and Arquimea Collaboration Circadian Therapeutics and ARQUIMEA sign a collaboration agreement for the development of casein kinase 1 inhibitors for the treatment of diseases affecting the nervous system Co-development of molecules as an...

New CT Research Published

New CT Research Published Adenosine integrates light and sleep signalling for the regulation of circadian timing in mice New research, published today in Nature Communications by Circadian Therapeutics founders and collaborators, identifies an adenosine-based...

Circadian Therapeutics Announce the Appointment of Dr. Mark Sampson

Circadian Therapeutics Announce the Appointment of Dr. Mark Sampson  Circadian Therapeutics Ltd is delighted to announce the appointment of Dr Mark Sampson as Chief Executive Officer and Board Member of the Company, effective 1st July 2020. Most recently Chief Medical...